BAY-27-9955

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 524379

CAS#: 202855-56-9

Description: BAY-27-9955 is glucagon receptor antagonist. It represents an innovative class of therapeutic agents for Type II diabetes.


Price and Availability

Size
Price

Size
Price

Size
Price

BAY-27-9955, purity > 98%, is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 524379
Name: BAY-27-9955
CAS#: 202855-56-9
Chemical Formula: C23H31FO
Exact Mass: 342.23589
Molecular Weight: 342.49
Elemental Analysis: C, 80.66; H, 9.12; F, 5.55; O, 4.67


Synonym: BAY-27-9955; BAY27-9955; BAY 27-9955; BAY-279955; BAY 279955; BAY279955.

IUPAC/Chemical Name: 1-(4'-fluoro-3,5-diisopropyl-6-propyl-[1,1'-biphenyl]-2-yl)ethanol

InChi Key: VDTWKXAPIQBOMO-UHFFFAOYSA-N

InChi Code: InChI=1S/C23H31FO/c1-7-8-19-20(14(2)3)13-21(15(4)5)22(16(6)25)23(19)17-9-11-18(24)12-10-17/h9-16,25H,7-8H2,1-6H3

SMILES Code: CC(O)C1=C(C(C)C)C=C(C(C)C)C(CCC)=C1C2=CC=C(F)C=C2


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Bagger JI, Knop FK, Holst JJ, Vilsbøll T. Glucagon antagonism as a potential therapeutic target in type 2 diabetes. Diabetes Obes Metab. 2011 Nov;13(11):965-71. doi: 10.1111/j.1463-1326.2011.01427.x. Review. PubMed PMID: 21615669.

2: Petersen KF, Sullivan JT. Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans. Diabetologia. 2001 Nov;44(11):2018-24. PubMed PMID: 11719833.